Views & Analysis Inhalation technology: the future of effective respiratory t... Simon Moore discusses non-clinical development channels: technical strategies, formulations and devices.
News FDA green lights CSL's once-monthly HAE drug Andembry CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
